The FDA on February 7, 2018 approved ZYTIGA® tablets in combination with Prednisone for metastatic high-risk Castration-Sensitive Prostate Cancer (CSPC). The FDA initially approved ZYTIGA® with prednisone in 2011 for patients with metastatic Castration-Resistant Prostate Cancer (CRPC), who had received prior chemotherapy, and expanded the indication in 2012 for patients with metastatic CRPC. ZYTIGA® is a product of Janssen Biotech Inc.
Bottom Ad
Advertisement
Subscribe
